NCT06412588View on ClinicalTrials.gov

Dual Therapy With Vonoprazan Plus Amoxicillin or Doxycycline Versus Bismuth Quadruple Therapy for Helicobacter Pylori Eradication:A Prospective, Multicenter, Open-label Randomized Controlled Study.

NANot yet recruitingINTERVENTIONAL
Enrollment

810

Participants

Timeline

Start Date

June 30, 2024

Primary Completion Date

October 31, 2024

Study Completion Date

December 31, 2024

Conditions
Helicobacter Pylori Infection
Interventions
DRUG

Vonoprazan+amoxicillin+doxycycline+bismuth for 14 days

Group A:The patient was treated with oral Vonoprazan 20 mg, bid + amoxicillin 1.0 g, bid + doxycycline 0.1 g, bid + bismuth for 14 days.

DRUG

Vonoprazan+Amoxicillin

Group B: Patients were treated with oral Vonoprazan 20mg, bid + amoxicillin 1.0g, bid for 14 days.

DRUG

Vonoprazan+doxycycline

Group C: Patients were treated with oral Vonoprazan 20 mg, bid + doxycycline 0.1 g, bid for 14 days.

All Listed Sponsors
lead

Nanjing First Hospital, Nanjing Medical University

OTHER

NCT06412588 - Dual Therapy With Vonoprazan Plus Amoxicillin or Doxycycline Versus Bismuth Quadruple Therapy for Helicobacter Pylori Eradication:A Prospective, Multicenter, Open-label Randomized Controlled Study. | Biotech Hunter | Biotech Hunter